B. Riley Securities Maintains Buy on Journey Medical, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel maintains a Buy rating on Journey Medical (NASDAQ:DERM) but lowers the price target from $6 to $3.
May 23, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B. Riley Securities maintains a Buy rating on Journey Medical (NASDAQ:DERM) but lowers the price target from $6 to $3.
The news directly mentions Journey Medical (NASDAQ:DERM) and the lowered price target by B. Riley Securities. While the Buy rating is maintained, the reduced price target may create mixed sentiment among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100